Skip to main content

Table 4 Solicited Grade 3/4 toxicities (physician evaluation) by baseline KI and age group

From: Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of life

  

n (%) of patients with maximum Grade 3/4 toxicity

 

Toxicity

All patients treated (N = 516)

Baseline KI ≥ 80% (N = 322)

Baseline KI < 80% (N = 193)

Age < 70 years (N = 329)

Age ≥ 70 years (N = 187)

Any toxicity

123 (23.8)

56 (17.4)

67 (34.7)

87 (26.4)

36 ( 19.3)

Fatigue/asthenia

82 (15.9)

32 ( 9.9)

50 (25.9)

54 (16.4)

28 ( 15.0)

Neutropenia

45 ( 8.7)

21 ( 6.5)

24 (12.4)

30 ( 9.1)

15 ( 8.0)

Nausea

16 ( 3.1)

6 ( 1.9)

10 ( 5.2)

10 ( 3.0)

6 ( 3.2)

Febrile neutropenia

10 ( 1.9)

3 ( 0.9)

7 ( 3.6)

6 ( 1.8)

4 ( 2.1)

Rash/desquamation

7 ( 1.4)

6 ( 1.9)

1 ( 0.5)

4 ( 1.2)

3 ( 1.6)

Stomatitis/pharyngitis

7 ( 1.4)

3 ( 0.9)

4 ( 2.1)

3 ( 0.9)

4 ( 2.1)

Mucositis

5 ( 1.0)

1 ( 0.3)

4 ( 2.1)

3 ( 0.9)

2 ( 1.1)

Vomiting

5 ( 1.0)

2 ( 0.6)

3 ( 1.6)

4 ( 1.2)

1 ( 0.5)

Diarrhea

2 ( 0.4)

1 ( 0.3)

1 ( 0.5)

2 ( 0.6)

0 ( 0.0)

  1. KI Karnofsky Index, N = total number of patients, n = number of patients